drugset / Trial / NCT00318968

Nexium RESPONSE Trial

NCT00318968

Phase 4 Completed 1000 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindDiagnostic

Summary

The primary purpose of the study is to develop, and test, an algorithm for identification of responders to empirical esomeprazole treatment in general practices.

Timeline

Start
2006-05
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg